Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 1Phase 1 1

Status

Completed 5Terminated 3

Sponsor Class

INDUSTRY 5OTHER 2NIH 2

Study Type

Interventional 5

Sponsor

Cancer Type

Sarcoma 2CNS 2Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Gliosarcoma 2Glioma 2Glioblastoma 2Brain Neoplasms 2Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Medulloblastoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 394Docetaxel 385Cisplatin 359pembrolizumab 343Bevacizumab 335Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × INDUSTRY × 1-methyltryptophan × Clear all
NCT02073123 2026-05-29

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

Lumos Pharma

Phase 1/2 Completed
131 enrolled 23 charts
Dermatologic

Melanoma

NCT02077881 2026-04-03

Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Lumos Pharma

Phase 1/2 Completed
157 enrolled 18 charts
Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT02052648 2024-03-27

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Lumos Pharma

Phase 1/2 Completed
160 enrolled 21 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT02502708 2020-06-04

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Lumos Pharma

Phase 1 Completed
81 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Gliosarcoma

NCT01792050 2020-05-28

Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer

Lumos Pharma

Phase 2 Completed
169 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡